AICAR

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide, also known as AICA riboside or Acadesine) is a nucleoside analogue that functions as an activator of AMPK (AMP-activated protein kinase) - the enzyme often called the "master regulator" of cellular energy metabolism. By mimicking cellular energy depletion, AICAR triggers a cascade of metabolic adaptations that closely parallel those induced by exercise.

AICAR is taken up by cells and phosphorylated to the monophosphate form (ZMP), which accumulates and activates AMPK. AMPK is activated when the AMP:ATP ratio rises - indicating that cellular energy stores are being depleted. Exercise causes exactly this shift, which is why AICAR is sometimes described as an "exercise mimetic." When AMPK is activated, it coordinates a comprehensive metabolic response to restore energy balance.

The downstream effects of AICAR-mediated AMPK activation include: increased glucose transporter GLUT4 translocation to the cell surface (enhancing glucose uptake independent of insulin), upregulation of fatty acid oxidation enzymes, stimulation of mitochondrial biogenesis via PGC-1alpha activation, suppression of mTOR signalling (reducing anabolic processes to conserve energy), and inhibition of inflammatory NF-kB signalling. The combination of increased glucose uptake, improved insulin sensitivity, and enhanced fat oxidation makes AICAR particularly relevant for metabolic syndrome and Type 2 diabetes research.

Perhaps the most striking published research on AICAR concerns physical performance. A landmark study in mice showed that AICAR treatment for 4 weeks increased running endurance by approximately 44%, even without exercise training. This effect was attributed to the remodelling of skeletal muscle toward a more oxidative, fatigue-resistant fibre type. This finding attracted significant interest from sports science researchers and also led WADA to add AICAR to the prohibited substances list.

The cardioprotective properties of AICAR are also well-documented. Multiple studies have shown that AICAR pre-treatment or administration during ischemia reduces myocardial infarct size and improves cardiac function in ischemia-reperfusion injury models. This effect is mediated through AMPK's ability to increase myocardial glucose utilisation even under anaerobic conditions (glycogenolysis) and through adenosine receptor activation.